Is NLRP3 or NLRP6 inflammasome activation associated with inflammation-related lung tumorigenesis induced by benzo(a)pyrene and lipopolysaccharide?

Gao, Min; Zhang, Peng; Huang, Li; Shao, Hua; Duan, Shuyin; Li, Chunyang; Zhang, Qiao; Wang, Wei; Wu, Yongjun; Wang, Jing; Liu, Hong; Feng, Feifei

doi:10.1016/j.ecoenv.2019.109687

Cited by 20 publications

(9 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The level of serum IL-18 in patients with breast cancer is also significantly higher than that in the healthy population (28). The present results were consistent with those reported in the literature (27,28). The number of regulatory T (Treg) cells significantly increases in breast cancer patients with lymph node metastasis, and the accumulation of Treg cells is associated with a short overall survival time in these patients (29).…”

Section: Discussionsupporting

confidence: 91%

“…By contrast, in benign breast fibroadenoma, IL-18 expression was at low levels or was negative. The level of serum IL-18 in patients with lung cancer, gastric cancer and hepatocarcinoma is significantly higher than that in the healthy population (27). The level of serum IL-18 in patients with breast cancer is also significantly higher than that in the healthy population (28).…”

Section: Discussionmentioning

confidence: 83%

See 1 more Smart Citation

Interleukin‑18 and ‑10 may be associated with lymph node metastasis in breast cancer

Ma¹,

Kong

2021

Oncol Lett

View full text Add to dashboard Cite

Reports on the expression of interleukin (IL)-10 in breast cancer are rare. The present study investigated the correlation between IL-18 and −10 in breast cancer, and assessed their clinical significance. Breast cancer (n=104) and breast fibroadenoma (n=31) tissues that were surgically removed and pathologically confirmed at Jinan Central Hospital Affiliated to Shandong University (Jinan, China) between November 2016 and January 2019 were collected. The expression of IL-18 and −10 was observed via immunohistochemistry. Breast cancer tissues were positive for IL-18 expression, which was primarily located in the cell membrane and cytoplasm. A significant difference in IL-18 expression was observed between breast cancer and fibroadenoma tissues (75.0 vs. 19.4%; P<0.001). IL-10 was expressed in breast cancer tissues and primarily located in the cytoplasm. Breast cancer tissues showed a significantly higher level of IL-10 expression compared with breast fibroadenoma tissues (78.8 vs. 22.6%; P<0.001). The regions of positive IL-18 and −10 expression were consistent. Tissues with positive expression of IL-18 and/or −10 had a significantly higher rate of lymph node metastasis than those with negative expression (IL-18: 67.9 vs. 42.3%; P=0.035; and IL-10: 67.1 vs. 40.9%; P=0.047). In conclusion, IL-18 is highly expressed in breast cancer and correlates positively with IL-10. Both IL-18 and −10 may correlate positively with lymph node metastasis in breast cancer.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 83%

Interleukin‑18 and ‑10 may be associated with lymph node metastasis in breast cancer

Ma¹,

Kong

2021

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…Aberrant activation of NLRP3 has been implicated in the pathogenesis of various autoimmune, chronic inflammatory, and metabolic diseases such as Cryopyrinassociated periodic syndrome, atherosclerosis, obesity, Alzheimer's disease, and Parkinson's disease (Rheinheimer et al, 2017;Heneka et al, 2018;Booshehri and Hoffman, 2019;Chen S. W. et al, 2020). Several studies point out that NLRP3 inflammasome plays a pivotal role in the occurrence of organ damage induced by environmental toxicants (Zhou et al, 2019) and pesticides (Gao et al, 2019), as well as drugs applied in the clinic (Jaeschke and Ramachandran, 2020). For example, NLRP3 inflammasome activation initiated by death-associated protein kinase (DAPK) or mitochondrial reactive oxygen species (mtROS) played a key role in causing acute lung injury, acute kidney injury, and long-term cognitive impairment due to paraquat exposure (Chen et al, 2015;Liu et al, 2015Liu et al, , 2017.…”

Section: Introductionmentioning

confidence: 99%

NLRP3 Inflammasome: A Promising Therapeutic Target for Drug-Induced Toxicity

Wei

Zhang

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Drug-induced toxicity, which impairs human organ function, is a serious problem during drug development that hinders the clinical use of many marketed drugs, and the underlying mechanisms are complicated. As a sensor of infections and external stimuli, nucleotide-binding oligomerization domain (NOD)-like receptor family pyrin domain containing 3 (NLRP3) inflammasome plays a key role in the pathological process of various diseases. In this review, we specifically focused on the role of NLRP3 inflammasome in drug-induced diverse organ toxicities, especially the hepatotoxicity, nephrotoxicity, and cardiotoxicity. NLRP3 inflammasome is involved in the initiation and deterioration of drug-induced toxicity through multiple signaling pathways. Therapeutic strategies via inhibiting NLRP3 inflammasome for drug-induced toxicity have made significant progress, especially in the protective effects of the phytochemicals. Growing evidence collected in this review indicates that NLRP3 is a promising therapeutic target for drug-induced toxicity.

show abstract

“…Accumulating evidence has revealed that inflammasomes are involved in the pathological processes of different tumors [14,30,31], but the specific molecular mechanisms remained incompletely elucidated. In this study, we identified different expression patterns and prognostic characteristics of IRGs among 10 cancers.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Inflammasome‐Related Signature Construction in Kidney Renal Clear Cell Carcinoma Based on a Pan‐Cancer Landscape

Zheng

Wang

Yue

et al. 2020

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. To investigate the expression patterns and prognostic characteristics of inflammasome-related genes (IRGs) across cancer types and develop a robust biomarker for the prognosis of KIRC. Methods. The differentially expressed IRGs and prognostic genes among 10 cancers were analyzed based on The Cancer Genome Atlas (TCGA) dataset. Subsequently, an IRGs risk signature was developed in KIRC. Its prognostic accuracy was evaluated by receiver operating characteristic (ROC) analysis. The independent predictive capacity was identified by stratification survival and multivariate Cox analyses. The gene ontology (GO) analysis and principal component analysis (PCA) were performed to explore biological functions of the IRGs signature in KIRC. Results. The expression patterns and prognostic association of IRGs varied from different cancers, while KIRC showed the most abundant survival-related dysregulated IRGs. The IRG signature for KIRC was able to independently predict survival, and the signature genes were mainly involved inimmune-related processes. Conclusions. The pan-cancer analysis provided a comprehensive landscape of IRGs across cancer types and identified a strong association between IRGs and the prognosis of KIRC. Further IRGs signature represented a reliable prognostic predictor for KIRC and verified the prognostic value of inflammasomes in KIRC, contributing to our understanding of therapies targeting inflammasomes for human cancers.

show abstract

Is NLRP3 or NLRP6 inflammasome activation associated with inflammation-related lung tumorigenesis induced by benzo(a)pyrene and lipopolysaccharide?

Cited by 20 publications

References 37 publications

Interleukin‑18 and ‑10 may be associated with lymph node metastasis in breast cancer

Interleukin‑18 and ‑10 may be associated with lymph node metastasis in breast cancer

NLRP3 Inflammasome: A Promising Therapeutic Target for Drug-Induced Toxicity

Prognostic Inflammasome‐Related Signature Construction in Kidney Renal Clear Cell Carcinoma Based on a Pan‐Cancer Landscape

Contact Info

Product

Resources

About